Advanced in Chromosome 4p Deletion

Ekrem O. Unal

Gaziantep, TR 
Advanced in Chromosome 4p Deletion
Gaziantep, TR 
OverviewLocationsClinical Research

Overview

Ekrem Unal practices in Gaziantep, Turkey. Mr. Unal is rated as an Advanced expert by MediFind in the treatment of Chromosome 4p Deletion. His top areas of expertise are Severe Congenital Neutropenia, Hemophagocytic Lymphohistiocytosis, Scurvy, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 167 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chromosome 4p Deletion.

Gender
Male

Locations

Gaziantep, Turkey
Other Locations
Ankara, Turkey
Erciyes, Turkey
Melikgazi, 38039, Turkey
Kayseri, Turkey
Talas, 38039, Turkey
Tekirdag, 59030, Turkey
Cebeci, 06580, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
Enrollment Status: Withdrawn
Publish Date: October 23, 2023
Intervention Type: Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

167 Total Publications

THE USE OF ORAL BISPHOSPHONATES IN REFRACTORY SEVERE HYPERCALCEMIA AFTER DENOSUMAB CESSATION.
THE USE OF ORAL BISPHOSPHONATES IN REFRACTORY SEVERE HYPERCALCEMIA AFTER DENOSUMAB CESSATION.
Journal: Acta endocrinologica (Bucharest, Romania : 2005)
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Unal's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 99 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile